Adrian Z. Stecyk, Chairman and CEO
Mr. Stecyk is a co-Founder of Griffin Securities. He has served as Chief Executive of Griffin Group plc, a London Stock Exchange, Alternative Investment Market listed company, Director of U.S. investments for U.K.-based Carter Barnard plc, and Managing Director of Griffin Capital Management, a registered U.S. investment advisor. Prior to entering the financial services industry, Mr. Stecyk served as VP of Product Development at publicly-listed Profit Technology. He began his professional career as an engineer with Charles Stark Draper Laboratory, a technology R&D company. Mr. Stecyk has a B.S. in Aerospace Engineering and an M.B.A. in Finance from Boston University. Print
astecyk@griffinsecurities.com | direct 212.509.7707 | cell 646.258.7269
Richard R. Vietor, Vice Chairman
Mr. Vietor has over 30 years of experience in managing global biotech and pharmaceutical research and investment banking, including leadership roles in numerous IPOs, secondary offerings and mergers. He was a Managing Director at Merrill Lynch in the Global Healthcare Investment Banking Group that was ranked number one in healthcare-related equity and equity-linked transactions in 2001 – 2002. Additionally, he was an Institutional Investor-ranked research analyst for 12 consecutive years. Mr. Vietor also served as a senior executive at Emdeon Corp. (now WebMD, Inc.) and played a major role in the WebMD Health public spinout. He serves on the Board of Directors for several private healthcare companies. He has a B.A. from Yale University and an M.B.A. from Columbia University Graduate School of Business. He is also a Chartered Financial Analyst (CFA).
rvietor@griffinsecurities.com | direct 646.442.1447 | cell 917.969.9962
Thomas J. McGahren, M.D., J.D., Senior Managing Director
Dr. McGahren brings diverse skill sets and expertise to his investment banking and strategic advisory position from his experience as a biotechnology analyst, consultant, attorney, and physician. Prior to Griffin, Tom was a Senior Director and senior biotech analyst at Merrill Lynch. Forbes ranked him the #1 Drugs Analyst in 2008. Prior to Wall Street, Tom was a litigator at the international law firm of Kaye Scholer from 1993 to 2001, where he represented pharmaceutical and biotechnology companies, particularly in patent, FDA, and corporate matters. Tom received his M.D. from the University of Virginia School of Medicine, a J.D. from the University of Texas School of Law, and a B.A. from Colgate University.
tmcgahren@griffinsecurities.com | direct 646.442.4253 | cell 917.826.8395
Howard S. Fischer, Managing Director
Howard Fischer is a former portfolio manager and research analyst with Silverback Asset Management’s Life Sciences fund. Previously, Howard was a senior investment banker with UBS Global Healthcare Investment banking.
hfischer@griffinsecurities.com | direct 646.442.4250 | cell 917.816.3088
Christine T. Fischette, Ph.D, Senior Advisor
Christine Fischette has over 25 years of experience in the Big Pharma/Biotech industry, having spent the majority of her career at Roche, Pfizer, and Novartis, where her last Big Pharma position was Head of Negotiation for a number of Therapeutic Business Franchise Units. She has executed multiple deals involving a variety of deal structures with large and small U.S., European, and Asian entities. She has had “hands-on” experience in general management, business development, and she was head of Pfizer’s U.S. commercial group for diabetes, having brought a diabetes drug, Glucotrol XL, to market, which eventually reached $350 million in sales. She directed its clinical development from IND to NDA to medical marketing, and prior to that engaged in bench research where she has over 50 publications, including Science.
cfischette@griffinsecurities.com | direct 646.442.4252 | cell 973.978.0671
Jay D. Kranzler, MD PhD, Senior Advisor
Dr. Kranzler is Chairman Emeritus, Founder, and former Chairman & CEO of Cypress Biosciences, Inc., which focuses on pain and central nervous system conditions. Dr. Kranzler developed a fibromyalgia syndrome drug from concept to market, including the design of clinical trials and regulatory path through Phase III trials and FDA approval. Dr. Kranzler is a recent recipient of the Award for Innovation from the International Society of CNS Drug Development. He is also an Executive in Residence at UCSD Rudy School of Management and an Adjunct Professor at the NYU Stern School of Business. Formerly, he was President & CEO of Cytel Corporation, a biotechnology company focused on immunology drug development, and a Management Consultant at McKinsey & Company, where he helped establish the Pharmaceutical Industry Practice. Dr. Kranzler has an M.D. with a focus in psychiatry and a Ph.D. in pharmacology from Yale University.
jkranzler@griffinsecurities.com | direct 646.442.1445 | cell 858.349.2323
John R. Toedtman, Senior Advisor
Mr. Toedtman’s 40 year business career includes senior management roles ranging from Fortune 100-company, Engelhard, to five entrepreneurial companies in the medical device, generic drug and healthcare IT sectors. He has been a board member of seven public companies and brings to Griffin’s clients substantial experience in M&A, technology transfer and corporate strategy. He was a Managing Director, Investment Banking, at Bluestone Capital. He has a B.A., Economics and M.A., International Economics, both from Georgetown University.
jtoedtman@griffinsecurities.com | direct 646.442.4249 | cell 908.229.9962
Mark H. Zizzamia, Managing Director
Mark joined Griffin Securities in 2002 as a Managing Director. Mark began his career at PaineWebber and Company and has over 17 years of experience within the financial industry working with both public and private companies. He has assisted in funding over 30 private companies, including TechRx and Health Dialog. At Griffin Mark is involved in all aspects of the investment banking group, including institutional and high net worth sales. Mark earned his B.A. in Political Science from Ohio Wesleyan University.
mzizzamia@griffinsecurities.com | direct 212.509.6511
Mark J. Alvino, Managing Director
Prior to joining Griffin Securities, Mark served as Managing Director at SCO Securities LLC, a life sciences merchant bank. His responsibilities included corporate outreach of portfolio companies and institutional sales for banking clients; he raised in excess of $500 million in private financings in over 20 transactions. Before his tenure at SCO, Mark worked as Senior Vice President at Feinstein Kean Healthcare, an Ogilvy Public Relations Worldwide Company. He also acted as senior counsel throughout the agency’s network of offices. Mark also served as Vice President of Allen & Caron, Inc., an investor relations agency. Mark received his B.B.A in Economics and Public Policy from The George Washington University.
malvino@griffinsecurities.com | direct 212.509.7512 | cell 646.246.7056
Sal Saraceno, Managing Director
Sal joined Griffin Securities in 2002 as Managing Director of the Griffin Private Equity Group. Sal began his career at Prudential Securities Incorporated and has over 19 years of experience within the financial industry working with both public and private companies in many capacities. At Griffin he is involved in all aspects of the investment banking group, including institutional and high net worth sales, sourcing and origination. Sal earned his B.A. in Economics from the University of Rhode Island.
ssaraceno@griffinsecurities.com | direct 212.509.6955
Holland Sullivan, Managing Director
Mr. Sullivan joined Griffin Securities in 2011 as a Managing Director. Holland began his career at Merrill Lynch and has previously worked at Goldman Sachs. Holland also served as a financial investigator on the Bernard L. Madoff fraud investigation. At Griffin, Holland is involved in all aspects of the investment banking group. He has a B.A. in Economics from Yale University and a J.D. from Baylor University School of Law, where he focused on business transactions and corporate law and was an editor of the Baylor Law Review. He is a licensed attorney in the State of Texas.
hsullivan@griffinsecurities.com | direct 646.442.4254 | cell 646.543.8824
Hunter Diamond, Research Associate
Hunter Diamond joined Griffin Securities in 2011. He specializes in analyzing small- and mid-capitalization investment opportunities. He is a Level II candidate in the CFA program. Hunter has a B.S. in Applied Economics and Management from Cornell University.